Advertisement

Biochemisches Screening für Neuralrohrdefekte und Down-Syndrom

  • W. Fuhrmann
Conference paper

Zusammenfassung

Die Bestimmung der Alpha-Fetoprotein-(AFP-)Konzentration im mütterlichen Serum in der 16.–18. Schwangerschaftswoche ist als allgemeiner Suchtest gut etabliert. Die Ergebnisse sind i. allg. zuverlässig, wenn das Schema beachtet, geeignete Kits verwandt und die dazugehörigen Normwerte zugrundegelegt werden (Abb. 1; Fuhrmann u. Weitzel 1985).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Cuckle HS, Wald NJ, Lindenbaum RH (1984) Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1:926–929PubMedCrossRefGoogle Scholar
  2. Cuckle HS, Wald NJ, Thompson S (1987) Estimating a woman’s risk of having a pregnancy associated with Down’s syndrome using her age and serum alpha-fetoprotein levels. Br J Obstet Gynecol 94:387–402CrossRefGoogle Scholar
  3. Cuckle H, Wald NJ, Stevenson JD et al. (1990) Maternal serum alpha-fetoprotein screening for open neural tube defects in twin pregnancies. Prenat Diagn 10:71–77PubMedCrossRefGoogle Scholar
  4. Fuhrmann W, Weitzel HK (1985) Maternal serum alpha-fetoprotein screening for neural tube defects. Report of a combined study in Germany and short overview on screening in populations with low birth prevalence of neural tube defects. Hum Genet 69:47–61PubMedCrossRefGoogle Scholar
  5. Fuhrmann W, Wendt P, Weitzel HK (1984) Maternal serum AFP as screening test for Down syndrome [letter]. Lancet II:413CrossRefGoogle Scholar
  6. Johnson JM, Harman CR, Evans JA, Macdonald K, Manning FA (1990) Maternal serum alpha-fetoprotein in twin pregnancy. Am J Obstet Gynecol 162:1020–1025PubMedGoogle Scholar
  7. Lustig L, Clarke S, Cunningham G, Schonberg R, Tompkinson G (1988) California’s experience with low MS-AFP results. AM J Med Genet 31:211–222PubMedCrossRefGoogle Scholar
  8. Macri JN, Kasturi RV, Krantz DA et al. (1990) Maternal serum Down syndrome screening -free beta-protein is a more effective marker than human chorionic gonadotropin. Am J Obstet Gynecol 163:1248–1253PubMedGoogle Scholar
  9. Martin AO, Dempsey LM, Minogue J, Liu K, Keller J, Tamura R, Freinkel N (1990) Maternal serum alpha-fetoprotein levels in pregnancies complicated by diabetes — implications for screening programms. Am J Obstet Gynecol 163:1209–1216PubMedGoogle Scholar
  10. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE (1984) An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 148:886–894PubMedGoogle Scholar
  11. Palomaki GE, Haddow JE (1987) Maternal serum alpha-fetoprotein, age, and Down syndrome risk. Am J Obstet Gynecol 156:460–463PubMedGoogle Scholar
  12. Special Report (1985) Maternal serum alpha-fetoprotein screening for neural tube defects. Results of a consensus meeting. Prenat Diagn 5:77–83CrossRefGoogle Scholar
  13. Wald NJ, Cuckle HS, Densem JW et al. (1988) Maternal serum screening for Down’s syndrome in early pregnancy. Br Med J 297:883–887CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • W. Fuhrmann

There are no affiliations available

Personalised recommendations